The phase 2b SYMMETRY trial, a multicenter, randomized, double-blind, placebo-controlled study, included 181 patients with compensated cirrhosis (Child-Pugh A) due to MASH (78% with histological diagnosis and 22% with cryptogenic cirrhosis attributed to MASH) assigned to receive efruxifermin at doses of 28 or 50 mg, or placebo (1:1:1), for 96 weeks
Learn about why getting enough magnesium, in the best form, and at the right doses, matters for you
plantarum NMC15-1 separately, has significantly increased plasma GLP-1 levels
10.2337/dc10-0856 287
Dr Drucker and his team have remained tenacious in their efforts to unpack how these drugs work, and this study deepens our understanding of metabolism and the complex brain-immune network that regulates it." The work is far from complete, however